Research Brief
Storing Cagriniltide: Best Practices
19 Citacoes PubMedRevisado por EspecialistasCertificado GMPUltima Revisao: julho de 2026
Pó Liofilizado
Store at -80°C por até 2 years or -20°C por até 1 year. Keep sealed, away from moisture and light, preferably under inert gas (N₂).
Solução Reconstituída
Store at -80°C por até 6 months or -20°C por até 1 month. Aliquot stock solutions para prevenir freeze-thaw cycles que degrade o peptideo.
Manuseio
White to off-white powder. Purity: ≥95–99.97% by HPLC/UPLC. Identity: LC-MS (~4409.01 Da). Physical stability: Thioflavin T (ThT) assay confirma >40 hours fibril-free under stress conditions.
Referencias
- Enebo LB, et al. Safety, tolerability, pharmacokinetics, and pharmacodynamics of concomitant administration of multiplos(as) doses of cagrilintide with semaglutide 2.4 mg for controle de peso: a randomised, controlled, phase 1b trial. Lancet, 397(10286), 1736-1748, 2021.
- Lau DCW, et al. Once-weekly cagrilintide for controle de peso in people with overweight and obesidade: a multicentre, randomised, duplo-cego, controlado por placebo and active-controlled, dose-finding phase 2 trial. Lancet, 398(10317), 2160-2172, 2021.
- Kruse T, et al. Development of Cagrilintide, a Long-Acting Amylin Analogue. Journal of Medicinal Chemistry, 64(15), 11183-11194, 2021.
- Frias JP, et al. Efficacy and safety of co-administered uma vez por semana cagrilintide 2.4 mg with uma vez por semana semaglutide 2.4 mg in diabetes tipo 2: a multicentre, randomised, duplo-cego, active-controlled, phase 2 trial. Lancet, 402(10403), 720-730, 2023.
- Garvey WT, et al. Coadministered Cagrilintide and Semaglutide in Adults with Overweight or Obesity. New England Journal of Medicine, 393(7), 635-647, 2025.
- Davies MJ, et al. Cagrilintide–Semaglutide in Adults with Overweight or Obesity and Type 2 Diabetes. New England Journal of Medicine, 393(7), 648-659, 2025.
- Verma S, et al. CagriSema Reduces Blood Pressure in Adults With Overweight or Obesity: REDEFINE 1. Hypertension, 83(2), e26055, 2026.
- Carvas AO, et al. Cagrilintide lowers bodyweight through brain amylin receptors 1 and 3. EBioMedicine, 118, 105836, 2025.
- Cao J, et al. Structural and dynamic features of cagrilintide binding to calcitonin and amylin receptors. Nature Communications, 16, 3389, 2025.
- Gu YM, et al. Structural and mechanistic insights into dual ativacao of cagrilintide in amylin and calcitonin receptors. Acta Pharmacologica Sinica, 47(1), 162-172, 2026.
- Wang Y, Feng Z, Yu L. The next frontier in metabolic health: Cagrilintide-Semaglutide e o(a) evolving landscape of therapies. The Innovation Medicine, 3(3), 100150, 2025.
- Fletcher MM, et al. AM833 Is a Novel Agonist of Calcitonin Family G Protein-Coupled Receptors: Pharmacological Comparison with Six Selective and Nonselective Agonists. JPET, 377(3), 417-440, 2021.
- Dahl K, et al. NN1213 – A Potent, Long-Acting, and Selective Analog of Human Amylin. Journal of Medicinal Chemistry, 67(14), 11688–11700, 2024.
- Becerril S, Frühbeck G. Cagrilintide plus semaglutide for obesidade management. Lancet, 397(10286), 1687-1689, 2021.
- D'Ascanio AM, et al. Cagrilintide: A Long-Acting Amylin Analog para o(a) Treatment of Obesity. Cardiology in Review, 32(1), 83-90, 2024.
- Mikhail N, Wali S. Cagrilintide Combined with Semaglutide: A New Approach for Treatment of Obesity and Type 2 Diabetes. Clinical Trials and Clinical Research, 2(5), 2023.
- Hales CM. Expanding the Treat-to-Target Toolbox for Obesity and Diabetes Care. New England Journal of Medicine, 393(7), 712-714, 2025.
- Gadde KM, Allison DB. Long-acting amylin analogue for reducao de peso. Lancet, 398(10317), 2132-2134, 2021.
- Dehestani B, et al. Amylin como um(a) Future Obesity Treatment. Journal of Obesity & Metabolic Syndrome, 30(4), 320-325, 2021.
Perguntas de Pesquisa Relacionadas
APENAS PARA USO EM PESQUISA
Este conteudo e fornecido apenas para fins educacionais e informativos. Os produtos sao fornecidos apenas para estudos in vitro e nao sao medicamentos, drogas ou suplementos. Nao aprovado pela FDA para prevenir, tratar ou curar qualquer condicao.